Patents by Inventor Catherine P. Prouty

Catherine P. Prouty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Uracil derivatives as AXL and c-MET kinase inhibitors
    Patent number: 10017496
    Abstract: The present invention provides compounds of Formula I or pharmaceutically acceptable salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, methods of treatment and uses thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: July 10, 2018
    Assignee: IGNYTA, INC.
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS
    Publication number: 20170320853
    Abstract: The present invention provides compounds of Formula I or pharmaceutically acceptable salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c,Y, R3, X, E and G are as defined herein, methods of treatment and uses thereof.
    Type: Application
    Filed: July 13, 2017
    Publication date: November 9, 2017
    Applicant: IGNYTA, INC.
    Inventors: Reddeppa Reddy DANDU, Robert L. HUDKINS, Kurt A. JOSEF, Catherine P. PROUTY, Rabindranath TRIPATHY
  • Uracil derivatives as AXL and c-MET kinase inhibitors
    Patent number: 9745283
    Abstract: The present application provides compounds of Formula I or salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: August 29, 2017
    Assignee: IGNYTA, INC.
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS
    Publication number: 20170050949
    Abstract: The present application provides compounds of Formula I or salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
    Type: Application
    Filed: November 8, 2016
    Publication date: February 23, 2017
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • Uracil derivatives as AXL and c-MET kinase inhibitors
    Patent number: 9522902
    Abstract: The present application provides compounds of Formula I or salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: December 20, 2016
    Assignee: Ignyta, Inc.
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • Uracil derivatives as AXL and c-MET kinase inhibitors
    Patent number: 9120778
    Abstract: The present application provides compounds of Formula I or salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: September 1, 2015
    Assignee: Ignyta, Inc.
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS
    Publication number: 20150210670
    Abstract: The present application provides compounds of Formula I or salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
    Type: Application
    Filed: April 8, 2015
    Publication date: July 30, 2015
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS
    Publication number: 20150209358
    Abstract: The present application provides compounds of Formula I or salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
    Type: Application
    Filed: April 8, 2015
    Publication date: July 30, 2015
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • Uracil derivatives as AXL and c-MET kinase inhibitors
    Patent number: 9029538
    Abstract: The present application provides compounds of Formula I or salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: May 12, 2015
    Assignee: Ignyta, Inc.
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • Substituted pyridazine derivatives
    Patent number: 8912183
    Abstract: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: December 16, 2014
    Assignee: Cephalon, Inc.
    Inventors: Robert L. Hudkins, Lars J. S. Knutsen, Catherine P. Prouty, Babu G. Sundar, Kevin J. Wells-Knecht
  • URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS
    Publication number: 20140275077
    Abstract: The present application provides compounds of Formula I or salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
    Type: Application
    Filed: May 13, 2014
    Publication date: September 18, 2014
    Applicant: Cephalon, Inc.
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • Substituted Pyridazine Derivatives
    Publication number: 20120004231
    Abstract: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
    Type: Application
    Filed: September 13, 2011
    Publication date: January 5, 2012
    Applicant: CEPHALON, INC.
    Inventors: Robert L. Hudkins, Lars J.S. Knutsen, Catherine P. Prouty, Babu G. Sundar, Kevin J. Wells-Knecht
  • Substituted pyridazine derivatives
    Patent number: 8076331
    Abstract: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: December 13, 2011
    Assignee: Cephalon, Inc.
    Inventors: Robert L. Hudkins, Lars J. S. Knutsen, Catherine P. Prouty, Babu G. Sundar, Kevin J. Wells-Knecht
  • Substituted pyridazine derivatives
    Publication number: 20100311752
    Abstract: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
    Type: Application
    Filed: July 29, 2010
    Publication date: December 9, 2010
    Applicant: CEPHALON, INC.
    Inventors: Robert L. Hudkins, Lars J.S. Knutsen, Catherine P. Prouty, Babu G. Sundar, Kevin J. Wells-Knecht
  • Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
    Patent number: 6780994
    Abstract: This invention relates to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: August 24, 2004
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Gee-Hong Kuo, William V. Murray, Catherine P. Prouty
  • Peptide analogs as irreversible interleukin-1beta protease inhibitors
    Publication number: 20040009923
    Abstract: Disclosed are compounds, compositions and methods for inhibiting interleukin-1&bgr; protease activity, the compounds having the formula (I).
    Type: Application
    Filed: January 16, 2003
    Publication date: January 15, 2004
    Inventors: Roland E. Dolle, Irennegbe K. Osifo, Stanley J. Schmidt, Denton W. Hoyer, Tina Morgan Ross, Prasad V. Chaturvedula, Catherine P. Prouty, Mohamed M.A. Awad, Joseph M. Salvino, James M. Rinker, Eric P. Lodge, Jasbir Singh, Mark A. Ator
  • Peptide analogs as irreversible interleukin-1&bgr; protease inhibitors
    Patent number: 6576614
    Abstract: Disclosed are compounds, compositions, and methods for inhibiting interleukin-1&bgr; protease activity, wherein the compounds are &agr;-substituted methyl ketones having formula (I) as set forth herein. These compounds are inhibitors of IL-1&bgr; converting enzyme and as such are useful as therapeutic agents for certain infectious diseases.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: June 10, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roland E. Dolle, Irennegbe K. Osifo, Stanley J. Schmidt, Denton W. Hoyer, Tina Morgan Ross, Prasad V. Chaturvedula, Catherine P. Prouty, Mohamed M. A. Awad, Joseph M. Salvino, James M. Rinker, Eric P. Lodge, Jasbir Singh, Mark A. Ator
  • Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
    Publication number: 20030088099
    Abstract: This invention relates to a series of heterocyclic substituted piperazines of Formula I 1
    Type: Application
    Filed: July 29, 2002
    Publication date: May 8, 2003
    Inventors: Gee-Hong Kuo, William V. Murray, Catherine P. Prouty
  • Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
    Publication number: 20020077476
    Abstract: This invention relates to a series of heterocyclic substituted piperazines of Formula I 1
    Type: Application
    Filed: December 11, 2001
    Publication date: June 20, 2002
    Inventors: Gee-Hong Kuo, William V. Murray, Catherine P. Prouty
  • N-(pyrimidinyl)-aspartic acid analogs as interleukin-1&bgr; converting enzyme inhibitors
    Patent number: 6407080
    Abstract: Disclosed are compounds, compositions and methods for inhibiting interleukin-1&bgr; (IL-&bgr;) protease activity. The compounds, N-(pyrimidinyl)-aspartic acid &agr;-substituted methyl ketones and aspartic acid aldehydes, have the formula (I) set out herein. These compounds are inhibitors of 1&bgr;-converting enzyme and as such are useful whenever such inhibition is desired. For example, they may be used as research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which 1L-&bgr; protease activity is implicated.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: June 18, 2002
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roland E. Dolle, Catherine P. Prouty, Prasad V. Chaturvedula, Stanley J. Schmidt